Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Prostate Cancer Tumor Board: Integration of Recent Data Sets Across Lines of Care

Release Date: April 30, 2019
Expiration Date: April 30, 2020
Media: Internet - based

Activity Overview

This online activity, Prostate Cancer Tumor Board: Integration of Recent Data Sets Across Lines of Care, is a case-based activity designed to update you on the latest data applicable to the care of your patients with prostate cancer. Using 4 patient case scenarios, the expert panel will discuss current and emerging treatment options for patients with prostate cancer across the spectrum of disease, including hormone-sensitive and -resistant, as well as metastatic and non-metastatic prostate cancer. This program will place cutting-edge data in the context of challenging patient cases to guide the integration of evidence-based advances in prostate cancer care into clinical practice.

Benefits of Participation

  • Gain expert perspective on emerging data for the care of your patients with prostate cancer
  • Learn about updated data from recently reported trials in prostate cancer and updates from ongoing trials with longer follow-up and new analyses
  • Hear expert opinion on steps in treatment and testing for complex patient cases of prostate cancer, based on real-world experience and clinical data
  • Explore future directions for the care of patients with prostate cancer through a discussion of ongoing or upcoming clinical trials

CME Activity Table of Contents

  • Pretest
  • Module 1: Introduction
  • Module 2: Tumor Board 1: Clinical Decision-Making in Prostate Cancer Based on Disease and Patient Factors
  • Module 3: Tumor Board 2: Challenges in Optimizing Treatment for Prostate Cancer With Biochemical Failure
  • Module 4: Tumor Board 3: Potential of Combination Therapy and Treatment Sequencing for Metastatic Hormone-Sensitive Prostate Cancer
  • Module 5: Tumor Board 4: Best Practices in Integrating Radium-223 Therapy for Patients With CRPC and Bone Metastasis
  • Module 6: Key Takeaways and Closing Remarks
  • Posttest

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, urologists, surgical oncologists, and radiation oncologists interested in the treatment of prostate cancer.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Discuss current approaches for diagnosis and risk stratification to inform treatment planning for patients with prostate cancer
  • Outline strategies to proactively identify and mitigate treatment-related toxicities for patients with prostate cancer in multidisciplinary settings
  • Evaluate practice-changing clinical trial findings concerning hormonal, chemotherapeutic, immunotherapeutic, and bone-directed treatment approaches for advanced/metastatic prostate cancer
  • Integrate recent clinical evidence into personalized treatment decision-making for patients with prostate cancer in multiple lines of care

Faculty, Staff, and Planners’ Disclosures


Daniel P. Petrylak
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosures: Grant/Research Support: Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Seattle Genetics; Consultant: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, Urogen.


Robert Den
Robert Den, MD
Associate Professor of Radiation Oncology and Cancer Biology
Urology Residency Program Director
Department of Radiation Oncology
Jefferson University Hospitals
Philadelphia, PA

Disclosures: No relevant financial relationships with commercial interests to disclose.

Robert Dreicer
Robert Dreicer, MD
Section Head, Medical Oncology
Deputy Director, University of Virginia Cancer Center
University of Virginia
Charlottesville, VA

Disclosures: Grant/Research Support: Seattle Genetics, Merck, Clovis, Roche, Janssen; Consultant: Janssen, AstraZeneca, Astellas, Pfizer, Eisai.

David I. Quinn
David I. Quinn, MD
Medical Director, Norris Cancer Hospital and Clinics
Section Head, Genitourinary Medical Oncology
Keck School of Medicine at USC
Los Angeles, CA

Disclosures: Grant/Research Support: Genentech, Millennium, GlaxoSmithKline; Consultant: Bayer, Astellas, Pfizer, Janssen, Dendreon, Merck, Genentech, Bristol-Myers Squibb, AstraZeneca, Exelixis, Novartis.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By